Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 is a promising next-generation ADC capable of targeting ovarian cancers with both high and low FRα expression. AZD5335 demonstrates efficacy in overcoming Elahere resistance and supports combined treatment strategies.
Authors
- Harini Shandilya (ORCID: https://orcid.org/0009-0002-6925-9785)
- Simon Christ (ORCID: https://orcid.org/0000-0003-2978-6548)
- John Meekin (ORCID: https://orcid.org/0009-0005-0983-6706)
- Simon Turner (ORCID: https://orcid.org/0009-0002-8014-4938)
- Ζήνων Ζήνωνος (ORCID: https://orcid.org/0000-0003-3301-1809)
- Sabina Cosulich (ORCID: https://orcid.org/0000-0001-9666-0510)
- Puja Sapra (ORCID: https://orcid.org/0000-0003-0954-2212)
- Kathryn Pugh (ORCID: https://orcid.org/0000-0003-0552-3508)
- Kevin Beaumont (ORCID: https://orcid.org/0000-0001-8721-6450)
- Alma Andoni (ORCID: https://orcid.org/0009-0006-2187-2790)
- Ali Saleh (ORCID: https://orcid.org/0000-0001-7663-5975)
- Ina Bisha (ORCID: https://orcid.org/0009-0009-8609-6376)
- Elaine M. Hurt (ORCID: https://orcid.org/0009-0005-3801-9537)
- Claire Myers (ORCID: https://orcid.org/0000-0002-5039-9238)
- Tima Thomas (ORCID: https://orcid.org/0009-0000-4664-8329)
- Michael L. Lehmann (ORCID: https://orcid.org/0000-0003-4476-8268)
- Benedicte Recolin (ORCID: https://orcid.org/0009-0001-7481-511X)
- John Hood (ORCID: https://orcid.org/0009-0007-9752-065X)
- Neki V. Patel (ORCID: https://orcid.org/0000-0002-6045-9089)
- Ravinder Tammali (ORCID: https://orcid.org/0000-0002-4318-2516)
- Judith Anderton (ORCID: https://orcid.org/0000-0002-8816-1196)
- Jason J. Zoeller (ORCID: https://orcid.org/0000-0003-3531-2111)
- Jon Chesebrough (ORCID: https://orcid.org/0000-0003-4885-3611)
- Jixin Wang (ORCID: https://orcid.org/0000-0001-7079-2056)
- Frances Neal (ORCID: https://orcid.org/0009-0009-5674-9209)
- K. Phin Chooi (ORCID: https://orcid.org/0000-0001-8657-1522)
- Rebecca Sargeant (ORCID: https://orcid.org/0009-0008-4348-9324)
- Paula G. Fraenkel (ORCID: https://orcid.org/0000-0001-8894-0117)
- Edward Rosfjord (ORCID: https://orcid.org/0000-0002-3449-7444)
- Shane Cronin (ORCID: https://orcid.org/0009-0002-4606-9209)
- Pat Mitchell (ORCID: https://orcid.org/0000-0002-3448-4512)
- Megan Cox (ORCID: https://orcid.org/0000-0002-7757-8965)
- Marco Gymnopoulos (ORCID: https://orcid.org/0009-0006-8851-3047)
- Tillmann Falck (ORCID: https://orcid.org/0009-0000-6827-9931)
- Diana Gasper (ORCID: https://orcid.org/0009-0008-1076-7439)
- Lisa Godfrey (ORCID: https://orcid.org/0009-0004-6312-6628)
- Tim Brier (ORCID: https://orcid.org/0009-0006-5218-1730)
- Roger B. Dodd (ORCID: https://orcid.org/0000-0003-4268-1863)
- Iris Dino (ORCID: https://orcid.org/0009-0008-1888-7048)
- Ana De Almeida (ORCID: https://orcid.org/0009-0002-2101-7058)
- Nancy Lee (ORCID: https://orcid.org/0009-0003-7972-1096)
- Lingyun Lan (ORCID: https://orcid.org/0009-0007-3311-8071)
- Christopher Ward (ORCID: https://orcid.org/0009-0002-3529-4312)
- Humaira Naseer (ORCID: https://orcid.org/0009-0002-6798-8175)
- Xhenifer Guza (ORCID: https://orcid.org/0009-0004-7535-461X)
- Isabella Tilmont (ORCID: https://orcid.org/0009-0005-7212-0276)
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (South Korea) (KR)
- ImageCat (United Kingdom) (GB)
- Massachusetts Medical Society (US)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Brazil) (BR)
- BSH Hausgeräte (Germany) (DE)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Poland) (PL)
- AstraZeneca (United States) (US)
- AstraZeneca (Germany) (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1749
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00